BioWorld

Jan. 10, 2005

Nexia Agreement For Asset Sale Awaiting OK From Shareholders

Canadian firm Nexia Biotechnologies Inc. entered an agreement to sell all of its assets and operations to a subsidiary of privately held PharmAthene Inc. for $18 million in cash and preferred shares and warrants. (BioWorld Today) Read More

Alteon Brings In $10M For Phase II Alagebrium Trials

New Chemo Approach Raises Bar In Cancer Drug Research

Depomed Bringing In $22M For Trials, Marketing Of GR Products

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...